Angioimmunoblastic T‐cell lymphoma (AITL) is a distinct peripheral T‐cell lymphoma
(PTCL) entity with peculiar clinical and pathological features. The recent identification of …

Anthracycline‐based chemotherapy remains standard treatment for peripheral T‐cell
lymphoma (PTCL) although its benefits have been questioned. We performed systematic …

To evaluate outcome and prognosis of patients with T-cell lymphoma we analyzed 343
patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study …

The peripheral T‐cell neoplasms are a biologically and clinically heterogeneous group of
rare disorders that result from clonal proliferation of mature post‐thymic lymphocytes …

Background Belinostat is a histone deacetylase inhibitor approved for relapsed refractory
peripheral T-cell lymphoma (PTCL). The primary objective of this study was to determine the …

T-cell and natural-killer (NK)-cell lymphomas are neoplasms with geographical variations in
frequencies. T-cell lymphomas are more prevalent in Asia than in Europe and North …

Background Outcomes with CHOP (cyclophosphamide, doxorubicin, vincristine, and
prednisolone) or CHOP-like chemotherapy in peripheral T-cell lymphoma are poor. We …

BACKGROUND: Patients with peripheral T‐cell lymphomas (PTCLs) have inferior
progression‐free survival (PFS) and overall survival (OS) compared with patients who have …

Purpose The present study was conducted to evaluate the safety and efficacy of
alemtuzumab plus CHOP chemotherapy for patients with peripheral T-cell lymphomas …

Novel, effective therapies are needed for peripheral T-cell non-Hodgkin's lymphoma (PTCL).
We treated 16 patients with a combination of gemcitabine, cisplatin and methylprednisolone …